HIGHFDA DRUG

Teva Clonidine Transdermal System Recall Expands Over CGMP Deviations, 124,054 Cartons Affected (202

Teva Pharmaceuticals recalled 124,054 cartons of Clonidine Transdermal System due to CGMP deviations from an unapproved raw material. The recall affects products sold in the United States. Consumers should stop using the product immediately and consult a healthcare provider for guidance.

Official notice

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DRUG
Recall date
March 19, 2026
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
March 19, 2026
Hazard Level
HIGH
Brands
CLONIDINE TRANSDERMAL SYSTEM, Actavis Pharma, Inc.
Category
Health & Personal Care
Sold At
Unknown
At-Risk Groups
GENERAL, PREGNANT, PETS

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
CLONIDINE TRANSDERMAL SYSTEM, Actavis Pharma, Inc.
Product type
Transdermal system (Medication)
Model numbers
Lot: 100060315, Exp.: 04/2026, 100068644, Exp.: 01/2027.
UPC codes
0591-3508, 0591-3509, 0591-3510, 0591-3508-54, 0591-3508-04, 0591-3509-54, 0591-3509-04, 0591-3510-54 +1 more
Sizes
0.1 mg/day patch
Sold at
Unknown

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    March 19, 2026

  2. Reported by FDA DRUG

    April 15, 2026

  3. RecallRadar source check

    April 22, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

CGMP Deviations: use of an unapproved raw material

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Teva Pharmaceuticals USA, Inc or your healthcare provider for guidance. Notification method: Letter

About This Product

Clonidine transdermal systems deliver a controlled amount of clonidine for hypertension management. They are prescribed and distributed to pharmacies and clinics.

Why This Is Dangerous

CGMP deviations indicate use of an unapproved raw material, which could lead to quality or safety concerns.

Industry Context

This recall is not necessarily part of a broader pattern but highlights CGMP deviations in drug manufacturing.

Real-World Impact

Direct impact on patients and clinics; potential disruption of therapy and need for immediate cessation and medical guidance.

Practical Guidance

How to identify if yours is affected

  1. Verify lot numbers 100060315 and 100068644.
  2. Check expiration dates 04/2026 and 01/2027.

Where to find product info

Recall notification letter and FDA enforcement page D-0472-2026.

What timeline to expect

Refunds or replacements described in recall letters; typically several weeks.

If the manufacturer is unresponsive

  • Escalate to pharmacist or healthcare provider.
  • Contact Teva Pharmaceuticals USA, Inc or distributor as indicated in recall notice.
  • File a formal consumer complaint with FDA if needed.

How to prevent similar issues

  • Verify CGMP compliance when sourcing drug products.
  • Watch for recall notices tied to manufacturing deviations.
  • Rely on pharmacies and clinics for stock verification.

Documentation advice

Keep recall notice, lot numbers, NDCs, expiration dates, and correspondence with suppliers.

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

Brand: CLONIDINE TRANSDERMAL SYSTEM. Manufacturer: Actavis Laboratories UT Inc., Salt Lake City, UT 84108. Distributor: Teva Pharmaceuticals USA, Inc. NDC 0591-3508-04 carton, NDC 0591-3508-54 pouch. Quantity: 124,054 cartons. Status: Active recall as of 2026-03-19. Distribution: Within the U.S.

Reported Incidents

No specific injuries or incidents are listed in the provided data.

Key Facts

  • Lot: 100060315 and Lot: 100068644
  • Exp. dates: 04/2026 and 01/2027
  • Manufacturer: Actavis Laboratories UT Inc., Salt Lake City, UT
  • Distributor: Teva Pharmaceuticals USA, Inc.

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERALPREGNANTPETS
Injury Types
POISONINGELECTRICALOTHER

Product Details

Model Numbers
Lot: 100060315
Exp.: 04/2026
100068644
Exp.: 01/2027.
UPC Codes
0591-3508
0591-3509
0591-3510
+6 more
Report Date
April 15, 2026
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls